Citizen Portal
Sign In

Senate committee advances bill to permit MDMA treatment for PTSD for first responders if FDA and DEA conditions met

Arizona State Senate Committee on Public Safety · February 18, 2026

Loading...

AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

SB 15‑42 would allow FDA‑approved, rescheduled MDMA products to be prescribed in Arizona and require workers' compensation coverage for an MDMA‑assisted PTSD treatment course for firefighters and certified peace officers, conditioned on FDA/DEA actions; committee advanced the bill with funding and research provisions.

Sponsor described SB 15‑42 as a conditional statutory framework that would allow MDMA‑assisted psychotherapy for post‑traumatic stress disorder if the Food and Drug Administration approves an MDMA product and the DEA reschedules it away from Schedule I. The bill would require the Industrial Commission to include MDMA treatment in workers' compensation coverage for firefighters and certified peace officers, and it authorizes a $10,000,000 appropriation to the Department of Health Services for clinical trials, applied research and clinician training if conditions are met.

Testimony from researchers and advocates noted promising trial results and the need to prepare clinicians and public institutions to support treatment protocols. Mike Williams described clinical outcomes and the importance of funding university settings to develop treatment guidelines, while senators asked about the size and source of the appropriation. The committee gave SB 15‑42 a due‑pass recommendation (vote ~6–1), with members noting fiscal and policy questions to resolve on the floor and in follow‑up hearings.